Ask AI
ProCE Banner Back Series Different Option in ...
ProCE Banner Series

A Different Option in the Treatment of Transfusion-Dependent Anemia in Lower-Risk MDS

Commercial speaker program deck to educate attendees about RYTELO (imetelstat)/ Hematology

Key Takeaways:

  • Recognize the ongoing unmet needs in transfusion dependent LR-MDS
  • Review the clinical evidence supporting Rytelo in ESA-relapsed/refractory or ESA-ineligible patients.
  • Understand practical treatment administration and adverse event management considerations.
  • Consider treatment goals with Rytelo to help address transfusion dependency or burden.

Learning Objectives:

  • Discuss the key unmet needs within LR-MDS
  • Highlight key efficacy and safety data for Rytelo.
  • Review Rytelo dosing and treatment administration, including dose modification considerations for the management of potential adverse events.

All Events

A Different Option in the Treatment of Transfusion-Dependent Anemia in Lower-Risk MDS

Upcoming Events

September

17

2026

12:15 PM - 1:00 PM Eastern Time (ET)

Virtual

Learn More

Additional Info

RYTELO INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION
RYTELO® (imetelstat) is indicated for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA).

IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Thrombocytopenia RYTELO® can cause thrombocytopenia based on laboratory values. In the clinical trial, new or worsening Grade 3 or 4 decreased platelets occurred in 65% of patients with MDS treated with RYTELO. Monitor patients with thrombocytopenia for bleeding. Monitor complete blood cell counts prior to initiation of RYTELO, weekly for the first two cycles, prior to each cycle thereafter, and as clinically indicated. Administer platelet transfusions as appropriate. Delay the next cycle and resume at the same or reduced dose, or discontinue as recommended.

Neutropenia
RYTELO can cause neutropenia based on laboratory values. In the clinical trial, new or worsening Grade 3 or 4 decreased neutrophils occurred in 72% of patients with MDS treated with RYTELO.

Monitor patients with Grade 3 or 4 neutropenia for infections, including sepsis. Monitor complete blood cell counts prior to initiation of RYTELO, weekly for the first two cycles, prior to each cycle thereafter, and as clinically indicated. Administer growth factors and anti-infective therapies for treatment or prophylaxis as appropriate. Delay the next cycle and resume at the same or reduced dose, or discontinue as recommended.

Infusion-Related Reactions
RYTELO can cause infusion-related reactions. In the clinical trial, infusion-related reactions occurred in 8% of patients with MDS treated with RYTELO; Grade 3 or 4 infusion-related reactions occurred in 1.7%, including hypertensive crisis (0.8%). The most common infusion-related reaction was headache (4.2%). Infusion-related reactions usually occur during or shortly after the end of the infusion.

Premedicate patients at least 30 minutes prior to infusion with diphenhydramine and hydrocortisone as recommended and monitor patients for at least one hour following the infusion as recommended. Manage symptoms of infusion-related reactions with supportive care and infusion interruptions, decrease infusion rate, or permanently discontinue as recommended.

Embryo-Fetal Toxicity
Based on animal findings, RYTELO can cause embryo-fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with RYTELO and for 1 week after the last dose. RYTELO HCP ISI 3/2025 VV-00015 ADVERSE REACTIONS Serious adverse reactions occurred in 32% of patients who received RYTELO. Serious adverse reactions in >2% of patients included sepsis (4.2%), fracture (3.4%), cardiac failure (2.5%), and hemorrhage (2.5%). Fatal adverse reactions occurred in 0.8% of patients who received RYTELO, including sepsis (0.8%).

Most common adverse reactions (≥10% with a difference between arms of >5% compared to placebo), including laboratory abnormalities, were decreased platelets, decreased white blood cells, decreased neutrophils, increased AST, increased alkaline phosphatase, increased ALT, fatigue, prolonged partial thromboplastin time, arthralgia/myalgia, COVID-19 infections, and headache.

©2026 Geron Corp. All rights reserved. Geron, the Geron logo, and RYTELO are registered trademarks of Geron Corporation.

Please see RYTELO (imetelstat) full Prescribing Information, including Medication Guide.

C-US-RYT-IM-0413 08/2026 

Acknowledgement

Sponsored By

Geron Corporation

Geron Corporation